Rapid
antigen tests are currently used for population screening
of COVID-19. However, they lack sensitivity and utilize antibodies
as receptors, which can only function in narrow temperature and pH
ranges. Consequently, molecularly imprinted polymer nanoparticles
(nanoMIPs) are synthetized with a fast (2 h) and scalable process
using merely a tiny SARS-CoV-2 fragment (∼10 amino acids).
The nanoMIPs rival the affinity of SARS-CoV-2 antibodies under standard
testing conditions and surpass them at elevated temperatures or in
acidic media. Therefore, nanoMIP sensors possess clear advantages
over antibody-based assays as they can function in various challenging
media. A thermal assay is developed with nanoMIPs electrografted onto
screen-printed electrodes to accurately quantify SARS-CoV-2 antigens.
Heat transfer-based measurements demonstrate superior detection limits
compared to commercial rapid antigen tests and most antigen tests
from the literature for both the alpha (∼9.9 fg mL
–1
) and delta (∼6.1 fg mL
–1
) variants of the
spike protein. A prototype assay is developed, which can rapidly (∼15
min) validate clinical patient samples with excellent sensitivity
and specificity. The straightforward epitope imprinting method and
high robustness of nanoMIPs produce a SARS-CoV-2 sensor with significant
commercial potential for population screening, in addition to the
possibility of measurements in diagnostically challenging environments.